Chiusura precedente | 45,99 |
Aperto | 45,81 |
Denaro | 45,10 x 900 |
Lettera | 46,31 x 1800 |
Min-Max giorno | 45,62 - 45,92 |
Intervallo di 52 settimane | 34,74 - 47,70 |
Volume | |
Media Volume | 1.009.461 |
Capitalizzazione | 10,136B |
Beta (5 anni mensile) | 0,42 |
Rapporto PE (ttm) | 30,06 |
EPS (ttm) | 1,52 |
Prossima data utili | 06 ago 2024 - 12 ago 2024 |
Rendimento e dividendo (futuro) | 1,28 (2,94%) |
Data ex dividendo | 30 gen 2024 |
Stima target 1A | 50,22 |
Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.) Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 Lon
QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosisVenlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Q
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence f